Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results


      News provided by

      AbbVie

      30 Jan, 2015, 12:47 GMT

      Share this article

      Share this article


      - Reports Full-Year Adjusted EPS of $3.32, Up 5.7 Percent; GAAP EPS $1.10

      - Delivers Fourth-Quarter Adjusted Revenue of $5.371 Billion, Up 8.9 Percent Over Fourth-Quarter 2013 (Up 5.1 Percent On a Reported Basis); GAAP Revenue $5.452 Billion

      - Revenue Growth in the Quarter Reflects 14.4 Percent Global Operational Sales Growth from HUMIRA (Up 10.6 Percent on a Reported Basis) and Strong Growth from Other Key Products

      - Delivers Adjusted Gross Margin Improvement of 410 Basis Points in the Fourth Quarter

      - Reports Fourth-Quarter Adjusted EPS of $0.89, Up 8.5 Percent; GAAP EPS ($0.51)

      - Launches Interferon-Free HCV Regimen Following Approval in United States, Europe and Canada

      - Confirms 2015 Adjusted EPS Guidance Range, Reflecting Industry-Leading Growth Versus the Prior Year

      NORTH CHICAGO, Illinois, Jan. 30, 2015 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2014.

      "AbbVie delivered exceptional performance in 2014 with sales and earnings well above our original projections for the year," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We returned to growth in 2014, a year ahead of schedule, and we expect to continue building on that momentum in 2015 with another year of strong performance. For 2015, we're focused on commercial and operational execution and the advancement of our promising pipeline as we build the company for long-term sustainable growth."

      Fourth-Quarter Results

      • Worldwide adjusted sales were $5.371 billion in the fourth quarter, up 5.1 percent. On an operational basis, adjusted sales increased 8.9 percent, excluding a 3.8 percent unfavorable impact from foreign exchange rate fluctuations. Worldwide sales under U.S. generally accepted accounting principles (GAAP) were $5.452 billion, up 6.7 percent on a reported basis and up 10.4 percent operationally.
      • Fourth-quarter sales growth was driven primarily by the continued strength of HUMIRA. Global HUMIRA sales increased 10.6 percent, or 14.4 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations. Total company sales growth was also driven by operational growth from Synagis, Creon and Duodopa.
      • The adjusted gross margin ratio in the fourth quarter was 81.2 percent, excluding intangible asset amortization and other specified items, up 410 basis points versus fourth-quarter 2013. The gross margin ratio under GAAP was 79.5 percent.
      • Adjusted selling, general and administrative (SG&A) expense was 29.1 percent of sales in the fourth quarter, reflecting the recent HCV launch and continued investment in our growth brands. On a GAAP basis, SG&A was 61.3 percent of sales, including specified items primarily related to the terminated Shire Plc (Shire) transaction.
      • Adjusted research and development (R&D) was 16.3 percent of sales in the quarter, reflecting funding actions in support of our mid- and late-stage pipeline and the continued pursuit of additional HUMIRA indications. On a GAAP basis, R&D was 16.1 percent of sales.
      • Net interest expense was $63 million on an adjusted basis and $129 million on a GAAP basis. The adjusted tax rate was 22.5 percent in the quarter and 21.9 percent on a GAAP basis.
      • Fourth-quarter diluted earnings (loss) per share were ($0.51) on a GAAP basis. Adjusted diluted earnings per share of $0.89 excludes intangible asset amortization expense and other specified items primarily related to the terminated Shire transaction. The impact of the Shire termination was comprised of the break fee ($0.66), mark-to-market and exit of certain foreign currency positions ($0.24) and other costs ($0.10). An additional ($0.08) of Shire specified charges will be booked in the first quarter of 2015 to reflect the completed liquidation of remaining foreign currency positions. 2015 GAAP guidance has been adjusted accordingly.

      Key Events from the Fourth Quarter

      • On Dec. 19, the U.S. Food and Drug Administration (FDA) approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. The approval of VIEKIRA PAK is supported by a robust clinical development program designed to study the safety and efficacy of the regimen in more than 2,300 enrolled patients across 25 countries. The program consisted of six pivotal Phase 3 studies, which demonstrated that VIEKIRA PAK cured 95-100 percent of GT1a and GT1b hepatitis C patients, including patients new and experienced to treatment, and patients with compensated cirrhosis, with less than 2 percent of patients experiencing virological failure. Additionally, more than 98 percent of patients in clinical trials completed a full course of therapy.
      • On Jan. 16, AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without RBV for patients with GT1 chronic HCV infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. Additionally, VIEKIRAX has been approved for use with RBV in genotype 4 chronic HCV patients.
      • On Jan. 12, AbbVie announced that the FDA approved DUOPA (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. In a clinical trial, patients treated with DUOPA experienced significantly greater improvement in "off" time (periods of poor mobility, slowness and stiffness) than patients treated with oral carbidopa-levodopa immediate release tablets.
      • AbbVie and Neurocrine Biosciences announced positive top-line results from the first of two ongoing Phase 3 clinical trials, designed to evaluate the efficacy and safety of elagolix in premenopausal women with endometriosis. Results from the trial show that after six months of treatment, both doses of elagolix (150 mg once daily and 200 mg twice daily) met the study's co-primary endpoints (p<0.001) of reducing scores of non-menstrual pelvic pain (NMPP) and menstrual pain (or dysmenorrhea), associated with endometriosis, at month three, as well as month six, as measured by the Daily Assessment of Endometriosis Pain scale. Elagolix, currently being investigated in patients with pain from endometriosis, inhibits gonadatropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels. To date, elagolix has been studied in over 40 clinical trials totaling more than 3,000 patients. A Phase 2b trial of elagolix for the treatment of uterine fibroids is also ongoing.
      • At the American Society of Hematology's 56th Annual Meeting, AbbVie presented new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells. In the study, the venetoclax group showed an overall response rate of 15.5 percent, with one patient achieving a complete response and four patients achieving a complete response with incomplete blood count recovery. These data indicate that further study of venetoclax in AML patients is warranted. Venetoclax will be studied in combination with other medicines sometimes used in treating patients with AML. Venetoclax is an investigational inhibitor of the B-cell lymphoma-2 (BCL-2) protein and is currently being evaluated in a Phase 3 clinical trial for the treatment of CLL and several other cancers.

      Confirming Full-Year 2015 Outlook

      AbbVie is confirming its adjusted diluted earnings-per-share guidance for the full-year 2015 of $4.25 to $4.45, which reflects industry-leading growth versus the prior year. The company's 2015 adjusted diluted earnings-per-share guidance excludes $0.34 per share of intangible asset amortization expense and other specified items. Including these items, AbbVie's diluted earnings-per-share guidance is $3.91 to $4.11 on a GAAP basis.

      About AbbVie

      AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our fourth-quarter performance. Participating on the call will be Rick Gonzalez, chairman and chief executive officer; Bill Chase, executive vice president and chief financial officer; Laura Schumacher, executive vice president, business development, external affairs and general counsel; Mike Severino, executive vice president, research and development and chief scientific officer; and Larry Peepo, vice president, investor relations. The call will be webcast through AbbVie's Web site at www.abbvieinvestor.com.

      Non-GAAP Financial Results

      Financial results for 2013 and 2014 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company's 2015 financial guidance is also being provided on both a reported and a non-GAAP basis.

      Forward-Looking Statements

      Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2013 Annual Report on Form 10-K and in Item 1A, "Risk Factors" of Part II of AbbVie's second quarter 2014 Quarterly Report on Form 10-Q, which have been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

      AbbVie Inc.

      Key Product Sales

      Quarter Ended Dec. 31, 2014

      (Unaudited)




      % Change vs. 4Q13


      Sales (in millions)


      International

      Total

      Total Adjusted Sales

      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      $3,083

      $2,288

      $5,371

      9.4%

      8.2%

      (0.2%)

      8.9%

      5.1%

      Humira

      1,932

      1,431

      3,363

      15.8

      12.7

      4.3

      14.4

      10.6

      Synagis

      --

      298

      298

      n/a

      4.9

      (5.0)

      4.9

      (5.0)

      AndroGel

      230

      --

      230

      (20.2)

      n/a

      n/a

      (20.2)

      (20.2)

      Lupron

      160

      47

      207

      2.5

      (4.6)

      (11.4)

      0.6

      (1.1)

      Kaletra

      50

      153

      203

      (20.5)

      2.3

      (7.5)

      (4.0)

      (11.1)

      Synthroid

      186

      --

      186

      (1.6)

      n/a

      n/a

      (1.6)

      (1.6)

      Creon

      151

      --

      151

      30.6

      n/a

      n/a

      30.6

      30.6

      Sevoflurane

      22

      98

      120

      (4.6)

      (18.7)

      (25.8)

      (16.7)

      (22.7)

      Dyslipidemia

      104

      --

      104

      13.6

      n/a

      n/a

      13.6

      13.6

      Duodopa

      --

      56

      56

      n/a

      25.4

      14.7

      25.4

      14.7

      Viekira

      48

      --

      48

      n/m

      n/a

      n/a

      n/m

      n/m


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations. Dyslipidemia includes sales of TriCor/Trilipix, Niaspan, Simcor and Advicor.


      n/a = not applicable

      n/m = not meaningful

      AbbVie Inc.

      Key Product Sales

      Twelve Months Ended Dec. 31, 2014

      (Unaudited)




      % Change vs. 12M13


      Sales (in millions)


      International

      Total

      Total Adjusted Sales

      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      $10,764

      $9,115

      $19,879

      5.7%

      8.9%

      5.9%

      7.1%

      5.8%

      Humira

      6,524

      6,019

      12,543

      24.6

      13.3

      11.0

      18.9

      17.7

      AndroGel

      934

      --

      934

      (9.7)

      n/a

      n/a

      (9.7)

      (9.7)

      Kaletra

      213

      657

      870

      (12.7)

      (4.5)

      (8.5)

      (6.6)

      (9.6)

      Synagis

      --

      835

      835

      n/a

      9.3

      1.0

      9.3

      1.0

      Lupron

      580

      198

      778

      2.5

      (5.4)

      (9.5)

      0.2

      (0.9)

      Synthroid

      709

      --

      709

      13.9

      n/a

      n/a

      13.9

      13.9

      Sevoflurane

      83

      467

      550

      7.1

      (1.0)

      (4.7)

      0.1

      (3.1)

      Creon

      516

      --

      516

      25.3

      n/a

      n/a

      25.3

      25.3

      Dyslipidemia

      328

      --

      328

      (69.5)

      n/a

      n/a

      (69.5)

      (69.5)

      Duodopa

      --

      220

      220

      n/a

      24.7

      23.5

      24.7

      23.5

      Viekira

      48

      --

      48

      n/m

      n/a

      n/a

      n/m

      n/m


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations. Dyslipidemia includes sales of TriCor/Trilipix, Niaspan, Simcor and Advicor.


      n/a = not applicable

      n/m = not meaningful

      AbbVie Inc.

      Consolidated Statements of Earnings (Loss)

      Quarter and Twelve Months Ended Dec. 31, 2014 and 2013

      (Unaudited) (In millions, except per share data)



      Fourth Quarter
      Ended Dec. 31


      Twelve Months
      Ended Dec. 31



      2014


      2013


      2014


      2013


      Net sales

      $5,452


      $5,111


      $19,960


      $18,790











      Cost of products sold

      1,119


      1,282


      4,426


      4,581


      Selling, general and administrative

      3,341


      1,448


      7,724


      5,352


      Research and development

      879


      798


      3,297


      2,855


      Acquired in-process research and development

      28


      48


      352


      338


      Other operating expense

      500


      --


      750


      --


      Total operating cost and expenses

      5,867


      3,576


      16,549


      13,126











      Operating earnings (loss)

      (415)


      1,535


      3,411


      5,664











      Interest expense, net

      129


      68


      391


      278


      Net foreign exchange loss

      496


      15


      678


      55


      Other (income) expense, net

      (3)


      13


      (27)


      (1)


      Earnings (loss) before income tax expense

      (1,037)


      1,439


      2,369


      5,332


      Income tax (benefit) expense

      (227)


      311


      595


      1,204


      Net earnings (loss)

      ($810)


      $1,128


      $1,774


      $4,128











      Diluted earnings (loss) per share

      ($0.51)


      $0.70


      $1.10


      $2.56


      Diluted earnings per share, excluding specified items

      $0.89


      $0.82


      $3.32


      $3.14

      a)










      Average diluted shares outstanding

      1,597


      1,608


      1,610


      1,604




      a)  Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.












      AbbVie Inc.


      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information


      Quarter Ended Dec. 31, 2014


      (Unaudited) (In millions, except per share data)



      1.

      Specified items impacted results as follows:





      4Q14



      Earnings (loss)

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      ($1,037)

      ($810)

      ($0.51)


      Adjusted for specified items:





      Other revenue

      (81)

      (81)

      (0.05)


      Intangible asset amortization

      96

      69

      0.04


      Acquired IPR&D

      28

      29

      0.02


      Calico collaboration

      500

      500

      0.31


      Shire transaction costs

      2,227

      1,623

      1.00


      Separation costs and other

      134

      116

      0.08


      As adjusted (non-GAAP)

      $1,867

      $1,446

      $0.89




      Other revenue principally includes royalty income from prior periods recognized in the fourth quarter of 2014 as a result of the settlement of a licensing arrangement. Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Acquired IPR&D primarily reflects an upfront payment related to a licensing arrangement with a third party. Calico collaboration reflects a payment related to the previously announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Separation costs and other is primarily related to the separation of AbbVie from Abbott.



      2.

      The impact of the specified items by line item was as follows:





      4Q14



      Net Sales

      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Other operating expense

      Interest expense (income)

      Net exchange (gain) loss


      As reported (GAAP)

      $5,452

      $1,119

      $3,341

      $879

      $28

      $500

      $129

      $496


      Adjusted for specified items:










      Other revenue

      (81)

      --

      --

      --

      --

      --

      --

      --


      Intangible asset amortization

      --

      (96)

      --

      --

      --

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      --

      (28)

      --

      --

      --


      Calico collaboration

      --

      --

      --

      --

      --

      (500)

      --

      --


      Shire transaction costs

      --

      --

      (1,660)

      --

      --

      --

      (66)

      (501)


      Separation costs and other

      --

      (15)

      (117)

      (2)

      --

      --

      --

      --


      As adjusted (non-GAAP)

      $5,371

      $1,008

      $1,564

      $877

      --

      --

      $63

      ($5)
















      3.

      The adjusted tax rate for the fourth quarter of 2014 was 22.5 percent, as detailed below:





      4Q14



      Pre-tax

      Income




      income (loss)

      taxes

      Tax rate


      As reported (GAAP)

      ($1,037)

      ($227)

      21.9%


      Specified items

      2,904

      648

      22.3%


      As adjusted (non-GAAP)

      $1,867

      $421

      22.5%


      AbbVie Inc.


      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information


      Quarter Ended Dec. 31, 2013


      (Unaudited) (In millions, except per share data)



      1.

      Specified items impacted results as follows:





      4Q13



      Earnings

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      $1,439

      $1,128

      $0.70


      Adjusted for specified items:





      Intangible asset amortization

      101

      76

      0.05


      Separation costs

      103

      66

      0.04


      Acquired IPR&D

      48

      48

      0.03


      Restructuring/Other

      11

      7

      0.00


      As adjusted (non-GAAP)

      $1,702

      $1,325

      $0.82




      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D reflects upfront payments related to previously announced collaborations. Restructuring/Other is primarily associated with previously announced restructuring activities.



      2.

      The impact of the specified items by line item was as follows:








      4Q13



      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Other (income) expense


      As reported (GAAP)

      $1,282

      $1,448

      $798

      $48

      $13


      Adjusted for specified items:







      Intangible asset amortization

      (101)

      --

      --

      --

      --


      Separation costs

      (5)

      (95)

      (3)

      --

      --


      Acquired IPR&D

      --

      --

      --

      (48)

      --


      Restructuring/Other

      (8)

      --

      --

      --

      (3)


      As adjusted (non-GAAP)

      $1,168

      $1,353

      $795

      --

      $10



      3.

      The adjusted tax rate for fourth-quarter 2013 was 22.2 percent, as detailed below:






      4Q13



      Pre-tax

      Income




      income

      taxes

      Tax rate


      As reported (GAAP)

      $1,439

      $311

      21.6%


      Specified items

      263

      66

      25.1%


      As adjusted (non-GAAP)

      $1,702

      $377

      22.2%










      AbbVie Inc.


      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information


      Twelve Months Ended Dec. 31, 2014


      (Unaudited) (In millions, except per share data)



      1.

      Specified items impacted results as follows:





      12M14



      Earnings

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      $2,369

      $1,774

      $1.10


      Adjusted for specified items:





      Other revenue

      (81)

      (81)

      (0.05)


      Intangible asset amortization

      403

      287

      0.18


      R&D

      40

      40

      0.02


      Acquired IPR&D

      352

      251

      0.15


      Calico collaboration

      750

      750

      0.46


      Shire transaction costs

      2,510

      1,802

      1.12


      Separation costs

      445

      385

      0.24


      Other

      136

      167

      0.10


      As adjusted (non-GAAP)

      $6,924

      $5,375

      $3.32




      Other revenue principally includes royalty income from prior periods recognized in the fourth quarter of 2014 as a result of the settlement of a licensing arrangement. Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. R&D is associated with payments for previously announced collaborations. Acquired IPR&D reflects upfront payments related to previously announced collaborations. Calico collaboration reflects payments related to the previously announced Calico collaboration. Shire transaction costs are expenses related to the terminated Shire transaction. Separation costs are related to the separation of AbbVie from Abbott. Other is primarily associated with the recognition of an additional year of the Branded Prescription Drug Fee as required by new IRS regulations.



      2.

      The impact of the specified items by line item was as follows:






      12M14



      Net Sales

      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Other operating expense

      Interest expense (income)

      Net exchange (gain) loss

      Other (income) expense


      As reported (GAAP)

      $19,960

      $4,426

      $7,724

      $3,297

      $352

      $750

      $391

      $678

      ($27)


      Adjusted for specified items:











      Other revenue

      (81)

      --

      --

      --

      --

      --

      --

      --

      --


      Intangible asset amortization

      --

      (403)

      --

      --

      --

      --

      --

      --

      --


      R&D

      --

      --

      --

      (40)

      --

      --

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      --

      (352)

      --

      --

      --

      --


      Calico collaboration

      --

      --

      --

      --

      --

      (750)

      --

      --

      --


      Shire transaction costs

      --

      --

      (1,703)

      --

      --

      --

      (141)

      (666)

      --


      Separation costs

      --

      (18)

      (422)

      (5)

      --

      --

      --

      --

      --


      Other

      --

      (58)

      (112)

      --

      --

      --

      --

      --

      34


      As adjusted (non-GAAP)

      $19,879

      $3,947

      $5,487

      $3,252

      --

      --

      $250

      $12

      $7



      3.        The adjusted tax rate for the full-year 2014 was 22.4 percent, as detailed below:






      12M14



      Pre-tax

      Income




      income

      taxes

      Tax rate


      As reported (GAAP)

      $2,369

      $595

      25.1%


      Specified items

      4,555

      954

      20.9%


      As adjusted (non-GAAP)

      $6,924

      $1,549

      22.4%


















      AbbVie Inc.


      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information


      Twelve Months Ended Dec. 31, 2013


      (Unaudited) (In millions, except per share data)



      1.

      Specified items impacted results as follows:





      12M13



      Earnings

      Diluted



      Pre-tax

      After-tax

      EPS


      As reported (GAAP)

      $5,332

      $4,128

      $2.56


      Adjusted for specified items:





      Intangible asset amortization

      509

      370

      0.23


      Separation costs

      255

      163

      0.10


      Acquired IPR&D

      338

      338

      0.21


      Restructuring/Other

      81

      67

      0.04


      As adjusted (non-GAAP)

      $6,515

      $5,066

      $3.14




      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities. Separation costs are expenses related to the separation of AbbVie from Abbott. Acquired IPR&D reflects upfront payments related to previously announced collaborations. Restructuring/Other is primarily associated with previously announced restructuring activities.




      2.

      The impact of the specified items by line item was as follows:








      12M13



      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Net foreign exchange (gain) loss

      Other (income) expense


      As reported (GAAP)

      $4,581

      $5,352

      $2,855

      $338

      $55

      ($1)


      Adjusted for specified items:








      Intangible asset amortization

      (509)

      --

      --

      --

      --

      --


      Separation costs

      (16)

      (230)

      (9)

      --

      --

      --


      Acquired IPR&D

      --

      --

      --

      (338)

      --

      --


      Restructuring/Other

      (5)

      (38)

      (15)

      --

      (11)

      (12)


      As adjusted (non-GAAP)

      $4,051

      $5,084

      $2,831

      --

      44

      ($13)

       

       

      3.

      The adjusted tax rate for the full-year 2013 was 22.2 percent, as detailed below:






      12M13



      Pre-tax

      Income




      income

      taxes

      Tax rate


      As reported (GAAP)

      $5,332

      $1,204

      22.6%


      Specified items

      1,183

      245

      20.7%


      As adjusted (non-GAAP)

      $6,515

      $1,449

      22.2%

      Modal title

      Also from this source

      AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

      AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with ...

      AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

      AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.